hemophilia

Novo gets PhIII hemophilia trials for a Roche rival back on track after completing work-around on blood clot threat
Novo gets PhIII hemophilia trials for a Roche rival back on track after completing work-around on blood clot threat
Endpoints
Novo Nordisk
hemophilia
concizumab
clinical trials
Flag link:
Sangamo R&D chief hits the exit as it splits R&D into separate units
Sangamo R&D chief hits the exit as it splits R&D into separate units
Fierce Biotech
Sangamo
R&D
Pfizer
hemophilia
Flag link:
Sigilon picks up $80M to test hemophilia cell therapy in humans
Sigilon picks up $80M to test hemophilia cell therapy in humans
Fierce Biotech
Siglion Therapeutics
cell terhapy
hemophilia
Flag link:
Novo Nordisk Pauses 3 Clinical Trials Testing Hemophilia Therapy
Novo Nordisk Pauses 3 Clinical Trials Testing Hemophilia Therapy
Xconomy
Novo Nordisk
clinical trials
concizumab
hemophilia
Flag link:
BioMarin Considers $3 Million Price Tag for New Hemophilia Gene Therapy
BioMarin Considers $3 Million Price Tag for New Hemophilia Gene Therapy
Motley Fool
Biomarin
JPMHC 2020
drug pricing
valrox
hemophilia
Flag link:
BioMarin sets gene therapy sights beyond hemophilia
BioMarin sets gene therapy sights beyond hemophilia
BioPharma Dive
Biomarin
hemophilia
gene therapy
Flag link:
Value-based pricing for gene therapy? Maybe not ready for hemophilia
Value-based pricing for gene therapy? Maybe not ready for hemophilia
Biopharma Dive
Biomarin
hemophilia
hemophilia A
gene therapy
valoctocogene roxaparvovec
uniQure
hemophilia B
etranadez
Flag link:
Sangamo keeps pressure on rivals with updated hemophilia data
Sangamo keeps pressure on rivals with updated hemophilia data
Biopharma Dive
ASH2019
Pfizer
Sangamo
hemophilia
SB-525
Flag link:
Why Novo Nordisk should buy Uniqure
Why Novo Nordisk should buy Uniqure
EP Vantage
Novo Nordisk
gene editing
hemophilia
uniQure
Bluebird Bio
Flag link:
The return of Vioxx: Can a drug once deemed deadly be relaunched to treat rare disease?
The return of Vioxx: Can a drug once deemed deadly be relaunched to treat rare disease?
Stat
Vioxx
hemophilia
generics
Tremeau Pharmaceuticals
hemophilic arthropathy
Flag link:
Novo taps bluebird bio for gene-editing tech
Novo taps bluebird bio for gene-editing tech
Fierce Biotech
Novo Nordisk
Bluebird Bio
R&D
gene editing
hemophilia
Flag link:
BioMarin drops lower dose of its hemophilia gene therapy as it eyes submissions by year-end
BioMarin drops lower dose of its hemophilia gene therapy as it eyes submissions by year-end
Fierce Biotech
Biomarin
hemophilia
gene therapy
valoctocogene roxaparvovec
valrox
hemophilia A
Flag link:
Thrashed by a 'surprise' rival, Sanofi writes off $2B on soured hemophilia deal
Thrashed by a 'surprise' rival, Sanofi writes off $2B on soured hemophilia deal
Endpoints
Sanofi
earnings
Roche
Hemlibra
hemophilia
Eloctate
Flag link:
Pharmacquired: Is $11B enough to secure Sanofi's spot in hemophilia?
Pharmacquired: Is $11B enough to secure Sanofi's spot in hemophilia?
Biopharma Dive
Sanofi
M&A
Bioverativ
hemophilia
gene therapy
Flag link:
Sangamo Stock Soars on Positive Hemophilia Treatment Trial
Sangamo Stock Soars on Positive Hemophilia Treatment Trial
TheStreet.com
Sangamo BioSciences
Pfizer
SB-525
hemophilia
clinical trials
Flag link:
IP trouble defers launch of Novo's long-acting hemophilia therapy
IP trouble defers launch of Novo's long-acting hemophilia therapy
Endpoints
Novo Nordisk
Eseproct
hemophilia
Roche
Hemlibra
Flag link:
FDA hemophilia meeting to discuss new efficacy endpoints
FDA hemophilia meeting to discuss new efficacy endpoints
BioCentury
FDA
clinical trials
hemophilia
Flag link:
Genentech and Hemophilia Patients Eye Oct. 4 for Hemlibra Ruling
Genentech and Hemophilia Patients Eye Oct. 4 for Hemlibra Ruling
BioSpace
FDA
Genentech
Hemlibra
hemophilia
Flag link:
Catalyst gives positive hemophilia update as 2 more subjects complete study
Catalyst gives positive hemophilia update as 2 more subjects complete study
Biopharma Dive
Catalyst Bioscences
hemophilia
clinical trials
Flag link:
What's Next for Spark Therapeutics
What's Next for Spark Therapeutics
Motley Fool
Spark Therapeutics
hemophilia
SPK-8011
Flag link:

Pages